Tazomeline

Tazomeline (LY-287,041) is a drug which acts as a non-selective muscarinic acetylcholine receptor agonist.[1][2] It was in clinical trials for the treatment of cognitive dysfunction such as that seen in Alzheimer's disease and schizophrenia, but development was apparently scrapped for unknown reasons.[1][2][3]

Tazomeline

Clinical data
ATC code	None
Identifiers
IUPAC name 5-[4-(hexylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine
CAS Number	131987-54-7
PubChem CID	131460
ChemSpider	116193
UNII	QDP6S14W5W
ChEMBL	ChEMBL131819
CompTox Dashboard (EPA)	DTXSID80157288
Chemical and physical data
Formula	C14H23N3S2
Molar mass	297.48 g·mol^−1
3D model (JSmol)	Interactive image
SMILES n2snc(/C1=C/CCN(C)C1)c2SCCCCCC

See also

• Alvameline
• Milameline
• Sabcomeline
• Xanomeline

References

1. Langmead CJ, Watson J, Reavill C (February 2008). "Muscarinic acetylcholine receptors as CNS drug targets". Pharmacology & Therapeutics. 117 (2): 232–43. doi:10.1016/j.pharmthera.2007.09.009. PMID 18082893.
2. Amos D Korczyn (October 2000). "Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease". Expert Opinion on Investigational Drugs. 9 (10): 2259–2267(9). doi:10.1517/13543784.9.10.2259. PMID 11060805.
3. Mashkovskii MD, Glushkov RG (April 2001). "Drugs for the Treatment of Alzheimer's Disease". Pharmaceutical Chemistry Journal. 35 (4): 179–182. doi:10.1023/A:1010474325601.